{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:13:17Z","timestamp":1774681997877,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Roche Pharma AG","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40120-019-00172-5","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T15:07:51Z","timestamp":1576163271000},"page":"67-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany"],"prefix":"10.1007","volume":"9","author":[{"given":"Sabrina","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Heidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pfaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunter","family":"Ladinek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"key":"172_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"A Compston","year":"2002","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(02)08220-X.","journal-title":"Lancet"},{"key":"172_CR2","unstructured":"Deutsche Gesellschaft f\u00fcr Neurologie, editor. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie: Diagnose und Therapie der Multiplen Sklerose. Berlin: Deutsche Gesellschaft f\u00fcr Neurologie"},{"key":"172_CR3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/1472-6963-14-381","volume":"14","author":"A H\u00f6er","year":"2014","unstructured":"H\u00f6er A, Schiffhorst G, Zimmermann A, et al. Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system. BMC Health Serv Res. 2014;14:381. https:\/\/doi.org\/10.1186\/1472-6963-14-381.","journal-title":"BMC Health Serv Res"},{"key":"172_CR4","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00115-014-4097-4","volume":"85","author":"G Petersen","year":"2014","unstructured":"Petersen G, Wittmann R, Arndt V, G\u00f6pffarth D. Epidemiologie der Multiplen Sklerose in Deutschland: regionale Unterschiede und Versorgungsstruktur in Abrechnungsdaten der gesetzlichen Krankenversicherung. Nervenarzt. 2014;85:990\u20138. https:\/\/doi.org\/10.1007\/s00115-014-4097-4.","journal-title":"Nervenarzt"},{"key":"172_CR5","unstructured":"S\u00f6llner. DGN\/KKNMS Leitlinie zur Diagnose und Therapie der MS. http:\/\/www.dmsg.de\/dokumentearchiv\/aktualisierung_herbst_dgnkknms_msll_20140813.pdf."},{"key":"172_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, Dissemination, and implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777\u201388.","journal-title":"Neurology"},{"key":"172_CR7","first-page":"703","volume":"16","author":"CV Asche","year":"2010","unstructured":"Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16:703\u201312.","journal-title":"J Manag Care Pharm"},{"key":"172_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1212\/CPJ.0b013e31824cb0ac","volume":"2","author":"O Khan","year":"2012","unstructured":"Khan O, Miller AE, Tornatore C, Phillips JT, Barnes CJ. Practice patterns of US neurologists in patients with SPMS and PPMS: a consensus study. Neurol Clin Pract. 2012;2:58\u201366. https:\/\/doi.org\/10.1212\/CPJ.0b013e31824cb0ac.","journal-title":"Neurol Clin Pract"},{"key":"172_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1212\/cpj.0b013e31824cb09b","volume":"2","author":"C Tornatore","year":"2012","unstructured":"Tornatore C, Phillips JT, Khan O, Miller AE, Barnes CJ. Practice patterns of US neurologists in patients with CIS, RRMS, or RIS: a consensus study. Neurol Clin Pract. 2012;2:48\u201357. https:\/\/doi.org\/10.1212\/cpj.0b013e31824cb09b.","journal-title":"Neurol Clin Pract"},{"key":"172_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049.","journal-title":"Mult Scler"},{"key":"172_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1606468.","journal-title":"N Engl J Med"},{"key":"172_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s11096-013-9857-x","volume":"35","author":"R Windt","year":"2013","unstructured":"Windt R, Glaeske G, Hoffmann F. Treatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patients. Int J Clin Pharm. 2013;35:1229\u201335. https:\/\/doi.org\/10.1007\/s11096-013-9857-x.","journal-title":"Int J Clin Pharm"},{"key":"172_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1352458517708125","volume":"23","author":"C Lebrun-Frenay","year":"2017","unstructured":"Lebrun-Frenay C, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: results for France. Mult Scler. 2017;23:65\u201377. https:\/\/doi.org\/10.1177\/1352458517708125.","journal-title":"Mult Scler"},{"key":"172_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1352458517708685","volume":"23","author":"P Calabrese","year":"2017","unstructured":"Calabrese P, Kobelt G, Berg J, Capsa D, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe: results for Switzerland. Mult Scler. 2017;23:192\u2013203. https:\/\/doi.org\/10.1177\/1352458517708685.","journal-title":"Mult Scler"},{"key":"172_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1352458517708100","volume":"23","author":"B Dubois","year":"2017","unstructured":"Dubois B, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: results for Belgium. Mult Scler. 2017;23:29\u201340. https:\/\/doi.org\/10.1177\/1352458517708100.","journal-title":"Mult Scler"},{"key":"172_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/1352458517708687","volume":"23","author":"A Thompson","year":"2017","unstructured":"Thompson A, Kobelt G, Berg J, Capsa D, Eriksson J, Miller D. New insights into the burden and costs of multiple sclerosis in Europe: results for the United Kingdom. Mult Scler. 2017;23:204\u201316. https:\/\/doi.org\/10.1177\/1352458517708687.","journal-title":"Mult Scler"},{"key":"172_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/1352458517708118","volume":"23","author":"PV Rasmussen","year":"2017","unstructured":"Rasmussen PV, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: results for Denmark. Mult Scler. 2017;23:53\u201364. https:\/\/doi.org\/10.1177\/1352458517708118.","journal-title":"Mult Scler"},{"key":"172_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1352458517708099","volume":"23","author":"T Berger","year":"2017","unstructured":"Berger T, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: results for Austria. Mult Scler. 2017;23:17\u201328. https:\/\/doi.org\/10.1177\/1352458517708099.","journal-title":"Mult Scler"},{"key":"172_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1352458517708176","volume":"23","author":"M Battaglia","year":"2017","unstructured":"Battaglia M, Kobelt G, Ponzio M, Berg J, Capsa D, Dal\u00e9n J. New insights into the burden and costs of multiple sclerosis in Europe: results for Italy. Mult Scler. 2017;23:104\u201316. https:\/\/doi.org\/10.1177\/1352458517708176.","journal-title":"Mult Scler"},{"key":"172_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123\u201336. https:\/\/doi.org\/10.1177\/1352458517694432.","journal-title":"Mult Scler"},{"key":"172_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1352458517708141","volume":"23","author":"P Flachenecker","year":"2017","unstructured":"Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: results for Germany. Mult Scler. 2017;23:78\u201390. https:\/\/doi.org\/10.1177\/1352458517708141.","journal-title":"Mult Scler"},{"key":"172_CR22","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/1472-6963-14-286","volume":"14","author":"CA Carroll","year":"2014","unstructured":"Carroll CA, Fairman KA, Lage MJ. Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data. BMC Health Serv Res. 2014;14:286. https:\/\/doi.org\/10.1186\/1472-6963-14-286.","journal-title":"BMC Health Serv Res"},{"key":"172_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000331043","volume":"66","author":"JP Reese","year":"2011","unstructured":"Reese JP, John A, Wienemann G, et al. Economic burden in a German cohort of patients with multiple sclerosis. Eur Neurol. 2011;66:311\u201321. https:\/\/doi.org\/10.1159\/000331043.","journal-title":"Eur Neurol"},{"key":"172_CR24","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index 2017. Oslo: WHO Collaborating Centre for Drug Statistics Methodology."},{"key":"172_CR25","unstructured":"Tagesdosen A-t-c-Km. Amtliche Fassung des ATC-Index mit DDD-Angaben f\u00fcr die Bundesrepublik Deutschland im Jahr 2016. K\u00f6ln: Deutsches Institut f\u00fcr Medizinische Dokumentation und Information (DIMDI); 2016. https:\/\/www.dimdi.de\/dynamic\/.downloads\/arzneimittel\/atcddd\/atc-ddd-amtlich-2016.pdf"},{"key":"172_CR26","unstructured":"Bundesanstalt f\u00fcr Arbeitsschutz und Arbeitsmedizin (BAuA). Volkswirtschaftliche Kosten durch Arbeitsunf\u00e4higkeit 2015. Dortmund: BAuA."},{"key":"172_CR27","first-page":"53","volume":"19","author":"GM Owens","year":"2013","unstructured":"Owens GM, Olvey EL, Skrepnek GH, Pill MW. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm. 2013;19:53.","journal-title":"J Manag Care Pharm"},{"key":"172_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","volume":"6","author":"DH Miller","year":"2007","unstructured":"Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6:903\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(07)70243-0.","journal-title":"Lancet Neurol"},{"key":"172_CR29","doi-asserted-by":"publisher","first-page":"817238","DOI":"10.1155\/2015\/817238","volume":"2015","author":"KA McKay","year":"2015","unstructured":"McKay KA, Kwan V, Duggan T, Tremlett H. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int. 2015;2015:817238. https:\/\/doi.org\/10.1155\/2015\/817238.","journal-title":"Biomed Res Int"},{"key":"172_CR30","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1212\/WNL.0b013e3181c5b47f","volume":"73","author":"M Koch","year":"2009","unstructured":"Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology. 2009;73:1996\u20132002. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c5b47f.","journal-title":"Neurology"},{"key":"172_CR31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00415-009-0039-7","volume":"256","author":"H Tremlett","year":"2009","unstructured":"Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol. 2009;256:374\u201381. https:\/\/doi.org\/10.1007\/s00415-009-0039-7.","journal-title":"J Neurol"},{"key":"172_CR32","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2147\/NDT.S132079","volume":"13","author":"HJ Gross","year":"2017","unstructured":"Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349\u201357. https:\/\/doi.org\/10.2147\/NDT.S132079.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"172_CR33","doi-asserted-by":"publisher","first-page":"e0133279","DOI":"10.1371\/journal.pone.0133279","volume":"10","author":"K Hansen","year":"2015","unstructured":"Hansen K, Sch\u00fcssel K, Kieble M, et al. Adherence to disease modifying drugs among patients with multiple sclerosis in germany: a retrospective cohort study. PLoS One. 2015;10:e0133279. https:\/\/doi.org\/10.1371\/journal.pone.0133279.","journal-title":"PLoS One"},{"key":"172_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/1352458517702549","volume":"24","author":"H Gyllensten","year":"2018","unstructured":"Gyllensten H, Wiberg M, Alexanderson K, Friberg E, Hillert J, Tingh\u00f6g P. Comparing costs of illness of multiple sclerosis in three different years: a population-based study. Mult Scler. 2018;24:520\u20138. https:\/\/doi.org\/10.1177\/1352458517702549.","journal-title":"Mult Scler"},{"key":"172_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/1472-6963-6-143","volume":"6","author":"V Casado","year":"2006","unstructured":"Casado V, Mart\u00ednez-Y\u00e9lamos S, Mart\u00ednez-Y\u00e9lamos A, et al. Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv Res. 2006;6:143. https:\/\/doi.org\/10.1186\/1472-6963-6-143.","journal-title":"BMC Health Serv Res"},{"key":"172_CR36","doi-asserted-by":"publisher","first-page":"101396","DOI":"10.1016\/j.msard.2019.101396","volume":"36","author":"D Bruno","year":"2019","unstructured":"Bruno D, Marc D, Ouarda P, et al. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. Mult Scler Relat Disord. 2019;36:101396. https:\/\/doi.org\/10.1016\/j.msard.2019.101396.","journal-title":"Mult Scler Relat Disord"},{"key":"172_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1352458517708141","volume":"23","author":"P Flachenecker","year":"2017","unstructured":"Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: results for Germany. Mult Scler. 2017;23:78\u201390. https:\/\/doi.org\/10.1177\/1352458517708141.","journal-title":"Mult Scler"},{"key":"172_CR38","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3111\/13696998.2014.940422","volume":"17","author":"N Bergvall","year":"2014","unstructured":"Bergvall N, Petrilla AA, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ. 2014;17:696\u2013707. https:\/\/doi.org\/10.3111\/13696998.2014.940422.","journal-title":"J Med Econ"},{"key":"172_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12883-019-1382-7","volume":"19","author":"N Bansback","year":"2019","unstructured":"Bansback N, Chiu JA, Carruthers R, et al. Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients. BMC Neurol. 2019;19:173. https:\/\/doi.org\/10.1186\/s12883-019-1382-7.","journal-title":"BMC Neurol"},{"key":"172_CR40","first-page":"s321","volume":"19","author":"K Noyes","year":"2013","unstructured":"Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care. 2013;19:s321\u201331.","journal-title":"Am J Manag Care"},{"key":"172_CR41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12913-018-3080-3","volume":"18","author":"FM Gansen","year":"2018","unstructured":"Gansen FM. Health economic evaluations based on routine data in Germany: a systematic review. BMC Health Serv Res. 2018;18:268. https:\/\/doi.org\/10.1186\/s12913-018-3080-3.","journal-title":"BMC Health Serv Res"},{"key":"172_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.healthpol.2016.01.007","volume":"120","author":"K Kreis","year":"2016","unstructured":"Kreis K, Neubauer S, Klora M, Lange A, Zeidler J. Status and perspectives of claims data analyses in Germany\u2014a systematic review. Health Policy. 2016;120:213\u201326. https:\/\/doi.org\/10.1016\/j.healthpol.2016.01.007.","journal-title":"Health Policy"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-019-00172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-019-00172-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-019-00172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T13:17:01Z","timestamp":1712841421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-019-00172-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["172"],"URL":"https:\/\/doi.org\/10.1007\/s40120-019-00172-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]},"assertion":[{"value":"9 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}